This repurposing of CD19 CAR T cells beyond their use for cancer may prove an effective and long-lasting therapy for patients with moderate to severe SLE and could be an option for other diseases where complete B cell depletion would provide relief. This evidence concerns the gene CD19 and systemic lupus erythematosus.